MedTrace Logo

The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma

NCT00498667 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2015-05-06

No results posted yet for this study

Summary

A retrospective analysis will be performed regarding the usefulness of PET/CT performed following 2 cycle of chemotherapy in evaluation of progression, free survival and overall survival of patients with aggressive non Hodgkin Lymphoma.

Conditions

  • Lymphoma; Large Cell (Diffuse) With Small Cell, Diffuse

Sponsors & Collaborators

  • Rambam Health Care Campus

    lead OTHER

Principal Investigators

  • Eldad J Dann, MD · RAMBAM health care campus,Rappaport faculty of medicine Technion Israel Technical institute

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2009-12-31
Completion
2014-12-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00498667 on ClinicalTrials.gov